Senate Bill Aims To Restrict Authorized Generics

Law360, New York (February 17, 2011, 2:24 PM EST) -- U.S. Senate Democrats are reviving a proposal to restrict brand-name pharmaceutical companies' ability to market authorized generics during the 180-day exclusivity window following the first successful challenge to a brand patent by a generic-drug maker.

S. 373, the Fair Prescription Drug Competition Act, was introduced in the Senate on Wednesday by Sens. Jay Rockefeller, D-W.Va.; Jeanne Shaheen, D-N.H.; Patrick Leahy, D-Vt.; Daniel Inouye, D-Hawaii; Debbie Stabenow, D-Mich.; and Charles Schumer, D-N.Y.

The legislation, which mirrors a similar bill introduced in several past sessions of Congress, aims...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.